Company

Location

Amt. (M)

Round

Details

Date

TOTAL: $933.86M

Acousia Therapeutics GmbH

Tubingen, Germany

$2.66

N/A

Acousia closed a new investment round of €2.5M (US$2.66M) led by the Boehringer Ingelheim Venture Fund and supported by the KfW, as well as new shareholder Axxam SpA

12/15/16

Amcure GmbH

Eggenstein-Leopoldshafen, Germany

$6.40

Series B

Amcure closed a €6M (US$6.4M) series B round from a consortium of existing investors and shareholders headed by LBBW Venture Capital, with participation from the KfW, MBG Mittelstaendische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Unternehmensbeteiligungs GmbH & Co. KG and Karlsruhe Institute of Technology (KIT) as well as private investors

12/15/16

Anabios Corp.

San Diego

$10.00

Series B

Anabios received a €4M (US$4.2M) investment from Principia SGR, a venture capital group based in Milano, Italy; the investment is part of Anabios' series B round, for a total of $10M

12/28/16

Apogen Biotechnologies Inc.

Seattle

$7.00

Series A

Accelerator Corp., of Seattle, participated in Apogen's $7M series A financing round; also involved in the financing were Abbvie Ventures, Alexandria Venture Investments, Arch Venture Partners, Eli Lilly and Co., Johnson & Johnson Innovation – JJDC, Inc., Watson Fund LP, WRF Capital and Wuxi Pharmatech

12/13/16

Axial Biotherapeutics Inc.

Boston

$19.15

Series A

Axial launched with a $19.15M series A financing led by Longwood Fund and Domain Associates, with participation from Kairos Ventures, Heritage Medical Systems and high net worth individuals based in Southern California

12/1/16

Bluerock Therapeutics

N/A

$225.00

Series A

Partners Bayer AG and Versant Ventures have committed $225M in series A financing to launch Bluerock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies

12/13/16

Circle Pharma Inc.

South San Francisco

$4.50

Series A

Circle Pharma issued more than $4.5M of shares of series A preferred stock; the series A financing was led by Mission Bay Capital, with New York-based Pfizer Inc., Shangpharma Investment Group Ltd. and a syndicated group of individual investors joining the round

12/22/16

Eutilex Co. Ltd.

South Korea

$18.00

Series A

Eutilex raised $18M in a series A round led by South Korean investment companies DS Investment Management Co. Ltd., Kolon Investment Pvt. Ltd., G.N.Tech Venture Capital Co. Ltd. And SNU Bio Angel

12/9/16

Exonate Ltd.

Cambridge, U.K.

$1.89

Angel

Exonate closed its third angel round, raising £1.5M (US$1.89M) from Angel Co. Fund, Australian venture fund, Uniseed, University of Bristol Enterprise Fund, Martlet of Cambridge, Wren Capital, O2h Ventures and additional angel investors

12/2/16

Goldinch Bio

Cambridge, Mass.

$55.00

Series A

Third Rock Ventures LLC invested $55M in a series A round

12/15/16

Impel Neuropharma Inc.

Seattle

$21.00

Series C

Impel Neuropharma closed a series C funding round of up to $36M with Venbio, 5AM Ventures and Vivo Capital, making equal investments that will be funded in two tranches; the company has received $21M in the initial tranche with the remaining $15M to be received upon accomplishment of certain development and business milestones

12/5/16

Intarcia Therapeutics Inc.

Boston

$421.00

Series EE

Intarcia completed its second close of a series EE financing, raising an additional $206M; it also raised $215M in a first close in September; the Bill & Melinda Gates Foundation provided a $50M investment; a third and final close of the series EE round is planned for the first quarter of 2017; Morgan Stanley & Co. LLC acted as sole structuring agent

12/28/16

Ixchelsis Ltd.

Sandwich, U.K.

$12.00

N/A

Pfizer Venture Investments and TVM Life Science Ventures VII said they are making an additional $12M investment in Ixchelsis

12/6/16

Medicenna Therapeutics Inc.

Vancouver, British Columbia

$7.50

N/A

Medicenna closed the fourth and final tranche of a private placement of special warrants to institutional and individual accredited investors and certain officers and directors of the company; Bloom Burton & Co. Ltd. acted as sole placement agent

12/2/16

Minomic International Ltd.

Sydney

$6.80

N/A

Minomic closed a round of A9.2M (US$6.8M) by raising another A5M (US$3.7M)

12/2/16

Ocugen Inc.

Aurora, Colo.

$1.00

Series A

Ocugen closed a $6M round of series A funding, including $1M in funds raised through EB5 Life Sciences LP; a group of ex-pharma executives led the raise

12/16/16

Oncorus Inc.

Cambridge, Mass.

$4.00

Series A

Oncorus said Astellas Venture Management LLC provided series A financing support to the company, increasing its series A proceeds by $4M to $61M; Astellas joins a team of investors led by MPM Capital and included Deerfield Management, Arkin Bio Ventures, Summit, N.J.-based Celgene Corp., Excelyrate Capital, Long March Investment Fund and MPM's Sunstates Fund

12/16/16

Pellepharm Inc.

Menlo Park, Calif.

N/A

Seed

Pellepharm has launched with financing from Bridgebio Pharma. The financing supports the development of topical patidegib, a hedgehog inhibitor to treat basal cell carcinomas (BCCs), including those in Gorlin syndrome, through the completion of two phase II trials that are underway, including one in Gorlin syndrome that just completed enrollment. In addition, the company has a drawable pool of capital from Bridgebio that enables it to finance future clinical trials through registration. The company was founded by a team of globally recognized experts in dermatology, oncology and hedgehog signaling.

12/9/16

Revolution Medicines Inc.

Redwood City, Calif.

$25.00

Series A

Revolution Medicines raised $25M in a series A extension financing; the Column Group joined founding investor Third Rock Ventures

12/21/16

SQZ Biotechnologies Co.

Boston

$4.00

N/A

Quark Venture Inc. invested $4M in SQZ

12/2/16

TCR2 Therapeutics Inc.

Cambridge, Mass.

$44.50

Series A

TCR2 Therapeutics raised $44.5M in a series A round led by MPM Capital and F2 Ventures

12/9/16

Tilt Biotherapeutics Ltd.

Helsinki

$4.26

N/A

Tilt closed a financing round of €4M (US$4.26M), consisting of loans from Tekes and equity investments from Lifeline Ventures and private investors

12/15/16

Vaccibody AS

Oslo, Norway

$25.00

N/A

Vaccibody engaged Arctic Securities AS in a private placement for the issuance of up to 800,000 new shares for up to NOK220M (US$23.5M), toward existing shareholders and selected institutional or professional investors

12/12/16

Vapogenix Inc.

Houston

$8.20

N/A

Vapogenix raised $8.2M; Pamoja Capital, prominent pain physicians and others invested in the round

12/9/16

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.